Country: Switzerland

ObelysQ SA

ObelysQ is a leading quality assurance consulting firm offering tailored solutions to the pharma industry aiming at enhancing compliance and improving processes in the execution of clinical trials. Our Headquarters are in Neuchâtel, with a branch in Poland and one being opened in the USA. With 50+ quality experts, we provide quality assurance and data privacy services all around the globe. GCP/GVP Consulting ObelysQ can provide support in the form of remote consulting done on an as-needed basis or simply be present there on your premises for the time you deem necessary. Together, we can discuss and evaluate the parameters of your project and further decide on what would be the best approach to support your endeavors. We do not believe in a one-size fits all solution and value the partnership and collaboration with our clients. GxP auditing ObelysQ can help you having meaningful and impactful audits. At an early stage, we can help you establish an audit strategy which will ensure an efficient use of your resources. You can also ask ObelysQ to conduct the audits on your behalf, our team has experience with various types of indications, dosage forms, vendors, and systems, and this on all continents! QMS set-up We will create tailored standard operating procedures that are compliant with the regulations, pragmatic enough to allow your staff to consistently and efficiently perform their duties, and adapted to your organization’s size and structure. With experience of developing SOPs for numerous sponsors and CROs, ObelysQ will build your SOPs from scratch or update your existing SOPs to optimize timelines, compliance, adherence and efficiency. Health Authority Inspection Bringing experience in successfully managing dozens of sponsor and site inspections (FDA, MHRA, EMA, CFDA, etc…), ObelysQ will provide your organization with an efficient and collaborative management of all Competent Authorities GCP inspections to maximize the chance of a successful outcome, while engaging your staff and decreasing anxiety. Our collaboration will include the development of a specific inspection plan, evaluation of the risks and potential issues in every aspect of your program/study, communication with all relevant staff, training, interview coaching, set up of the inspections facilities, inspection hosting and/or back room support, development or responses to inspection findings. You can pick and choose depending on your needs and the nature of the inspection. Training In order to provide the best in class GCP/GVP training, we develop and adapt out training material based on your specific needs, regulations and their updates, business best practices and inspection findings. You decide the approach that fits your needs best as we offer all solutions: presenting GCP at Investigator meetings, conducting face to face training sessions, providing online training tailored to your type of project. Gap Analysis ObelysQ will conduct a full clinical gap analysis to assess your staff, facilities, processes, documents and data. You will receive a detailed report with pragmatic recommendations tailored to your organization to strengthen your clinical processes and ensure GCP compliance and inspection readiness. ObelysQ will also support their implementation and conduct an effectiveness check to ensure objectives were met. You can decide to focus on the entire clinical organization or on a single unit such as your Clinical Qualtiy Unit. We’ll identify all areas for improvement to ensure you have best-in-class Clinical Quality structure and processes. Data Protection Support ObelysQ can help increase compliance through a series of distinct services that allows our clients to ensure their staff is adequately informed of important data protection concepts and regulations. -Data protection training (on-site or e-learning) -Data protection (GDPR) gap analysis -Development of data protjection strategies, SOPs and tools -Externalized Data Protection Oficer(DPO) specifically for clinical trials -GDPR-compliance assessment of vendors.

Read More

NXI Therapeutics AG

NXI Therapeutics creates tomorrow’s disruptive immunotherapies that maintain immunocompetence. The company has identified first-in-class 3rd generation isoform-specific BET inhibitors that provide a potent, autoimmune-selective immunomodulation. This unique profile may truly unlock the potential of epigenetic BET inhibition for the treatment of autoimmune and inflammatory diseases. The company focuses on clinical applications in T cell-mediated autoimmune skin conditions.

Read More

Nutrix AG

Nutrix built a “Hormonal Intelligence” platform combining proprietary salivary biosensors with AI-driven care. It developed cortiSense, the first Swiss non-invasive cortisol sensor (CES Innovation Award 2025), and is expanding with tSense for testosterone (CES Innovation Award 2026). Both deliver medical-grade results at home in 3 minutes

Read More

nuance biotechnology

nu.ance biotechnology was founded by a group of entrepreneurs with a desire to merge technical and scientific specialist knowledge and expertise into the development and commercialization of innovative feed additive products. Sharing a novel view on animal health and resilience, we decided to follow a different path by acknowledging the fusion of the synergetic power of nature and cutting-edge nutrition. Our goal is to enhance animal resilience by supporting and influencing modern nutritional strategies with the development of future-forward nutrition solutions.

Read More

NovoViz SA

NovoViz is a Swiss fabless semiconductor innovator advancing computational single-photon imaging. We deliver scalable, high‑performance SPAD sensor solutions for machine vision, industrial automation, and edge computing. Our mission is to make cutting‑edge single‑photon technology accessible for industrial integration.

Read More

Novochizol SA

Novochizol SA researches and develops applications of NOVOCHIZOL™ , a fist-in-class technology that transforms individual chitosan molecules into well-defined nanoparticles. Novochizol improves the characteristics of ordinary chitosans and yields materials with new properties for applications in pharma, medtech, biotech, agriculture, and other industries. As a biocompatible biopolymer, NOVOCHIZOL™ improves the interfacing of different materials with living tissues. In in vitro diagnostics, Novochizol™ enables better nucleic acid purification and improves the specificity and sensitivity of PCR and immunological tests. As an excipient, Novochizol™ can be used to formulate small molecules, nucleic acids, peptides, proteins, viruses and cells. Novochizol™ formulations are strongly bioadherent, enabling sustained release of active ingredients, deep tissue penetration and intracellular targeting. NOVOCHIZOL™ is the first chitosan-based nanoparticle compatible with pharma standards. Its starting material is a new type of biotech chitosan, manufactured by Alpha Chitin, a producer of precision chitosans with precise and reproducible physico-chemical characteristics, guaranteed traceability and batch-to-batch reproducibility. NOVOCHIZOL™ synthesis is also extremely well-defined: it is based on monomolecular, intramolecular cross-linking, in which a single linear molecule of chitosan is folded into a single nanoparticle. The outcome of the reactionis fully defined by the characteristics of the starting chitosan and the amount of the added cross-linking agent. In other words, the number of variables during synthesis is reduced to a strict minimum, yielding highly uniform particles that are easy to customize, to characterize, and to reproduce, in compliance with the regulatory requitements. NOVOCHIZOL™ meets all the criteria for Safe-by-Desing manufacturing. As a drug delivery system, NOVOCHIZOL™ allows rapid formulation of all classes of active pharmaceutical ingredients: small molecules, peptides, nucleic acids, proteins, polysaccharides, viruses and mammalian cells. Different dosage forms are possible: injectables, topicals, aerosols, and implant coatings. The resulting formulations are strongly bioaadhesive and mucoadhesive, enabling localized delivery of APIs at the sire of administration, without systemic distribution. NOVOCHIZOL™ formulations ensure protection of fragile APIs against biological degradation and have customizable release properties. Importantly, they can be endocytosed at the site of administration in a receptor-independent manner, making it possible for APIs to reach new, intracelluar therapeutic targets. NOVOCHIZOL™ has an excellent safety profile as a polysaccharide that is fully biocompatible and biodegradable. NOVOCHIZOL™ business model is based on two, convergent strategies: bona fide drug development and excipient registration and out-licensing of Novochizol™ as a drug delivery system. We are currently focusing on the development of new nanomedicines in immuno-concology (intra-tumoral delivery of therapetucally-effective doses of native and engineered cytokines), in respiratory diseases (inhalable drug delivery systems), and in cosmetic surgery and osteoarthritis (development of long-lasting formulations of hyaluronic acid as dermo fillers and for joint repair). We are leveraging on these early-stage drug development projects to reach regulatory qualification of Novochizol™ for pharmaceutical use in 2024) and to develop a rapid formulation testing platform for any API candidate that needs to be delivered to specific tissues or organs, avoiding systemic distribution. NOVOCHIZOL™ aims to become the first chitosan nanoparticle approved for pharmaceutical use

Read More

NOBLE Rides – JINMA Rides

NOBLE Rides is part of the JINMA Rides group. We are one of the three largest manufacturers of amusement rides worldwide. Our products are manufactured according tot he EN and ASTM standard. All products are ready for TÜV certification. We export to over 40 countries worldwide. NOBLE Rides products are designed and engineered in Europe, manufactured in China and TÜV SÜD or NORD certified.

Read More

Ninsun Biotech

Ninsun Biotech is a start-up based in Valais at BioArk. It operates in the field of oncology and is revolutionising the marking of cancer stem cells by offering, for the first time, a specific biomarker for several cancers, including lung, breast and colon. Current technologies rely on the use of a combination of non-specific markers, so Ninsun Biotech is breaking new ground with its patented technology, offering new prospects in terms of diagnosis, monitoring (companion tests) and, ultimately, individualised treatment for patients. Ninsun Biotech’s stem cell marking kits are also perfectly compatible with the current clinical chain of patient management.

Read More

NewBiologix

NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines. NewBiologix is committed to improve the generation and production of viral vectors used in gene and cell therapies by combining innovative and proprietary bioinformatics platform with advanced R&D experimentation. Next-generation sequencing (NGS)-based genome characterization will be used to develop an innovative and proprietary bioinformatics platform that will help cell line engineering through a combination of exceptionally in-depth datasets, sophisticated genomic analyses, and advanced R&D experimentation. NewBiologix’ technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines engineered to be readily adaptable to meet the viral vector demands and requirements over a full range of products. With a strong Series A financing and an experienced start-up team established, NewBiologix anticipates cell line prototypes will be ready for beta testing with key collaborators by 2024 with the goal of commercially available viral production cell line lines by 2025. | NewBiologix is a technology innovation company developing proprietary platforms for the improved production of viral vectors used in gene and cell therapies. The company offers best-in-class rAAV variant screening, proprietary engineered HEK293 cell line programs, and next-generation sequencing (NGS) services including PacBio, Illumina, Nanopore, and Bionano. Our suite of technologies aims to help biopharmaceutical companies develop transformative gene therapies faster, safer, and at scale. | NewBiologix SA is a biotechnology company developing Swiss-engineered solutions for gene and cell therapy production. Specializing in cell line engineering, the company offers advanced cell lines and a genomic analytical platform, including the Xcell Engineered HEK293 Cell Line, custom high-quality AAV production, and cellular and viral genomic characterization with integrated bioinformatics. Our expertise enables partners to develop and scale gene therapies faster, while ensuring they are safer and more reliable.

Read More